Dover Advisors LLC Has $1.92 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Dover Advisors LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,280 shares of the company’s stock after selling 74 shares during the period. Johnson & Johnson accounts for 1.1% of Dover Advisors LLC’s holdings, making the stock its 27th largest position. Dover Advisors LLC’s holdings in Johnson & Johnson were worth $1,921,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in JNJ. Knuff & Co LLC increased its position in Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after purchasing an additional 64 shares during the period. Vertex Planning Partners LLC increased its position in shares of Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after buying an additional 65 shares during the period. Werba Rubin Papier Wealth Management raised its stake in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after buying an additional 66 shares during the last quarter. Corepath Wealth Partners LLC lifted its holdings in Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock valued at $287,000 after buying an additional 70 shares during the period. Finally, Lifestyle Asset Management Inc. boosted its position in Johnson & Johnson by 4.7% during the fourth quarter. Lifestyle Asset Management Inc. now owns 1,560 shares of the company’s stock valued at $226,000 after acquiring an additional 70 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research analyst reports. Leerink Partners lowered their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $162.75 on Thursday. The business’s fifty day simple moving average is $150.08 and its 200 day simple moving average is $155.97. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a market capitalization of $391.83 billion, a P/E ratio of 24.47, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.29 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.